Table 3. Combination treatments and mortality.
| Combination type | n (%) | 14-day mortality | 30-day mortality |
|---|---|---|---|
| Combination with one antibiotic | 27 (43%) | 6 (22.2%) | 11 (40.7%) |
| Fosfomycin plus meropenem | 12 (19%) | 3 (25%) | 5 (41.6%) |
| Fosfomycin plus colistin/polymyxin B | 7 (11%) | 2 (28.5%) | 4 (57.1%) |
| Fosfomycin plus amikacin/gentamycin | 3 (5%) | 1 (33.3%) | 1 (33.3%) |
| Fosfomycin plus others* | 5 (8%) | 0 (0%) | 1 (20%) |
| Combination with two antibiotics | 35 (57%) | 16 (45.7%) | 23 (65.7%) |
| Fosfomycin plus meropenem plus colistin/polymyxin B | 14 (23%) | 7 (50%) | 10 (71.4%) |
| Fosfomycin plus meropenem plus amikacin/gentamycin | 9 (15%) | 3 (33.3%) | 4 (44.4%) |
| Fosfomycin plus colistin/polymyxin B plus amikacin/gentamycin | 2 (3%) | 0 (0%) | 1 (50%) |
| Fosfomycin plus others* | 10 (16%) | 6 (60%) | 8 (80%) |
*
Others: ceftazidim/avibactam, cefoperazone/sulbactam, tigecycline, TMP/SMX, ciprofloxacin, and levofloxacin.